Serotonin excess secondary to a combination of a small dose of duloxetine and tramadol

DOI Web Site
  • NAKAMURA Yoshimi
    Department of Anesthesiology and Pain Medicine, Gifu University Graduate School of Medicine
  • YOSHIMURA Noritaka
    Department of Anesthesiology and Pain Medicine, Gifu University Graduate School of Medicine
  • TANABE Kumiko
    Department of Anesthesiology and Pain Medicine, Gifu University Graduate School of Medicine
  • YAMAGUCHI Shinobu
    Department of Anesthesiology and Pain Medicine, Gifu University Graduate School of Medicine
  • SUGIYAMA Yoko
    Department of Anesthesiology and Pain Medicine, Gifu University Graduate School of Medicine
  • IIDA Hiroki
    Department of Anesthesiology and Pain Medicine, Gifu University Graduate School of Medicine

Bibliographic Information

Other Title
  • 少量のデュロキセチンとトラマドールの併用によるセロトニン過剰状態
  • 症例 少量のデュロキセチンとトラマドールの併用によるセロトニン過剰状態
  • ショウレイ ショウリョウ ノ デュロキセチン ト トラマドール ノ ヘイヨウ ニ ヨル セロトニン カジョウ ジョウタイ

Search this article

Description

<p>Serotonin syndrome is caused by excessive serotonin stimulation at the central and peripheral nerve postsynaptic synapse. Patients present with changes in mental status and symptoms of neuromuscular and autonomic dysfunction. We report 3 cases of serotonergic disorder in patients with chronic pain who received a small dose of duloxetine and tramadol. Patients presented with mental symptoms, sweating, palpitations, and tremor after receiving duloxetine and tramadol. Notably, immediate symptomatic improvement was observed with discontinuation of both medicines or of duloxetine alone. Patients were diagnosed with serotonin syndrome based on careful history-taking. Tramadol metabolism is inhibited by duloxetine (which inhibits CYP2D6). Therefore, it is speculated that the increase in blood concentration of tramadol caused serotonin excess in these patients. Inhibition of tramadol metabolism was attributed to the administration of bicalutamide (CYP3A4 inhibitor) in 1 patient. Clinicians must be aware of drug-drug interactions and closely monitor adverse effects, particularly in patients with chronic pain who receive polypharmacy.</p>

Journal

Related Projects

See more

Keywords

Details 詳細情報について

Report a problem

Back to top